Joshua H. Lipschutz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joshua H. Lipschutz has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Xiaofeng Zuo
Department of Medicine, Medical University of South Carolina, Charleston, USA
12 shared publicationsYujing Dang
Department of Medicine, Medical University of South Carolina, Charleston, USA
7 shared publications- Ashish Kumar Solanki
Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
6 shared publications Yanhui Su
Department of Medicine, Medical University of South Carolina, Charleston, USA
6 shared publications- Glenn Prazere Lobo
Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Lions Research Building, 2001 6th Street SE, Minneapolis, MN 55455, USA
5 shared publications Soo Young Choi
From the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425 and
5 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Springer Nature in npj Metabolic Health and Disease
- Vol. 4 (1) , 14
Beta 2 adrenergic receptor agonists as a treatment for metabolic dysfunction-associated steatohepatitis (MASH)
MASH is a leading cause of liver transplantation. Here, we investigated formoterol, a long-acting β2 adrenergic receptor agonist (LABA), in MASH. Mice treated with a high-fat diet (HFD) for sixteen weeks developed liver steatosis and were treated with formoterol or vehicle for four weeks. Steatosis largely resolved following formoterol treatment. To investigate mechanism, we evaluated mitochondrial biogenesis and found in HFD mice treated with formoterol versus vehicle that: PGC1α levels and electron transport chain components were significantly higher; mitochondrial number was increased; and lipids were decreased. Human HepaRG liver cells were then exposed to free fatty acids and/or formoterol. Formoterol attenuated lipid accumulation and increased ATP-linked basal and maximal respiration. Finally, a retrospective analysis of 59,644 patients with MASH showed that patients taking LABAs had fewer complications of advanced liver disease and lower mortality. Together, these data raise the possibility that LABAs, especially formoterol, could be a novel MASH treatment.
- 25 March 2026
- Published by Springer Nature in npj Metabolic Health and Disease
- Vol. 4 (1) , 14
Open AccessBeta 2 adrenergic receptor agonists as a treatment for metabolic dysfunction-associated steatohepatitis (MASH)
MASH is a leading cause of liver transplantation. Here, we investigated formoterol, a long-acting β2 adrenergic receptor agonist (LABA), in MASH. Mice treated with a high-fat diet (HFD) for sixteen weeks developed liver steatosis and were treated with formoterol or vehicle for four weeks. Steatosis largely resolved following formoterol treatment. To investigate mechanism, we evaluated mitochondrial biogenesis and found in HFD mice treated with formoterol versus vehicle that: PGC1α levels and electron transport chain components were significantly higher; mitochondrial number was increased; and lipids were decreased. Human HepaRG liver cells were then exposed to free fatty acids and/or formoterol. Formoterol attenuated lipid accumulation and increased ATP-linked basal and maximal respiration. Finally, a retrospective analysis of 59,644 patients with MASH showed that patients taking LABAs had fewer complications of advanced liver disease and lower mortality. Together, these data raise the possibility that LABAs, especially formoterol, could be a novel MASH treatment.
- Open Access
- 4 March 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (3) , 681-695
Deficiency of exocyst complex component Exoc5 exacerbates the progression of kidney fibrosis
Fibrosis, an undesirable side effect of the repair process, is due to aberrant cell differentiation and is a typical cause of progressive diseases including chronic kidney disease (CKD). Exocyst complex component 5 (Exoc5), a central component of the highly-conserved eight-protein exocyst complex, is involved in cell differentiation and maturation; however, the role of Exoc5 in fibrosis remains to be defined. Here we investigate the role and underlying molecular mechanisms of Exoc5 on kidney development and fibrosis using kidney proximal tubule cell-specific Exoc5- knockout (PT–Exoc5 KO ) mice generated by crossing Exoc5 f/f with PEPCK-cre mice. Exoc5-knockout mice showed normal kidney structure and function. Unilateral ureteral obstruction (UUO) led to kidney fibrosis with decreased Exoc5 expression, and Exoc5 knockout worsened the fibrosis. Exoc5 knockout alone increased Yes-associated protein (YAP) expression and exacerbated UUO-induced YAP activation and the expression of CTGF and CYR61, products of YAP, compared with wild-type (PT–Exoc5 WT ) mice. UUO induced paired box 2 (Pax2, which is mainly expressed during kidney development) expression in both mice, and the UUO-induced Pax2 expression in PT–Exoc5 KO was greater than in PT–Exoc5 WT mice. In HK-2 cells, a human proximal tubule cell, EXOC5 downregulation by siRNA increased YAP and Pax2 expression. EXOC5 downregulation augmented TGF-β-induced YAP activation and epithelial-to-mesenchymal transition. Taken together, our data demonstrate that Exoc5 plays a protective role in kidney fibrosis, implying that Exoc5 could potentially serve as a therapeutic target for the regulation of fibrosis.
- 4 March 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (3) , 681-695
Open AccessDeficiency of exocyst complex component Exoc5 exacerbates the progression of kidney fibrosis
Fibrosis, an undesirable side effect of the repair process, is due to aberrant cell differentiation and is a typical cause of progressive diseases including chronic kidney disease (CKD). Exocyst complex component 5 (Exoc5), a central component of the highly-conserved eight-protein exocyst complex, is involved in cell differentiation and maturation; however, the role of Exoc5 in fibrosis remains to be defined. Here we investigate the role and underlying molecular mechanisms of Exoc5 on kidney development and fibrosis using kidney proximal tubule cell-specific Exoc5- knockout (PT–Exoc5 KO ) mice generated by crossing Exoc5 f/f with PEPCK-cre mice. Exoc5-knockout mice showed normal kidney structure and function. Unilateral ureteral obstruction (UUO) led to kidney fibrosis with decreased Exoc5 expression, and Exoc5 knockout worsened the fibrosis. Exoc5 knockout alone increased Yes-associated protein (YAP) expression and exacerbated UUO-induced YAP activation and the expression of CTGF and CYR61, products of YAP, compared with wild-type (PT–Exoc5 WT ) mice. UUO induced paired box 2 (Pax2, which is mainly expressed during kidney development) expression in both mice, and the UUO-induced Pax2 expression in PT–Exoc5 KO was greater than in PT–Exoc5 WT mice. In HK-2 cells, a human proximal tubule cell, EXOC5 downregulation by siRNA increased YAP and Pax2 expression. EXOC5 downregulation augmented TGF-β-induced YAP activation and epithelial-to-mesenchymal transition. Taken together, our data demonstrate that Exoc5 plays a protective role in kidney fibrosis, implying that Exoc5 could potentially serve as a therapeutic target for the regulation of fibrosis.
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (1) , C107-C117
Serine proteases and protease-activated receptors signaling in the kidney
Protease-activated receptors (PARs) are a subclass of G protein-coupled receptors activated by serine proteases via proteolytic cleavage, triggering intracellular signaling cascades that regulate various physiological processes. Recent research underscores the significance of serine proteases and PARs in renal physiology, particularly in glomerular cells, where they modulate podocyte function, mesangial matrix dynamics, and filtration barrier integrity. In this review, we discuss the current knowledge on the function of key serine proteases in the kidney and their interactions with specific PARs, with a focus on the glomerulus and pathological implications. Among PARs, PAR1 is the most abundantly expressed in the kidney and plays a pivotal role in renal pathology. Serine proteases such as thrombin, plasmin, and kallikrein interact with PARs to regulate renal function; however, dysregulation in this pathway may contribute to diabetic nephropathy, glomerulosclerosis, fibrosis, and chronic kidney disease. Overall, the role of PARs in glomerular pathophysiology represents a critical area of research with significant therapeutic implications. Continued investigation into the mechanisms of serine proteases and PARs is essential for advancing targeted therapies for glomerular disorders.
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (1) , C107-C117
Serine proteases and protease-activated receptors signaling in the kidney
Protease-activated receptors (PARs) are a subclass of G protein-coupled receptors activated by serine proteases via proteolytic cleavage, triggering intracellular signaling cascades that regulate various physiological processes. Recent research underscores the significance of serine proteases and PARs in renal physiology, particularly in glomerular cells, where they modulate podocyte function, mesangial matrix dynamics, and filtration barrier integrity. In this review, we discuss the current knowledge on the function of key serine proteases in the kidney and their interactions with specific PARs, with a focus on the glomerulus and pathological implications. Among PARs, PAR1 is the most abundantly expressed in the kidney and plays a pivotal role in renal pathology. Serine proteases such as thrombin, plasmin, and kallikrein interact with PARs to regulate renal function; however, dysregulation in this pathway may contribute to diabetic nephropathy, glomerulosclerosis, fibrosis, and chronic kidney disease. Overall, the role of PARs in glomerular pathophysiology represents a critical area of research with significant therapeutic implications. Continued investigation into the mechanisms of serine proteases and PARs is essential for advancing targeted therapies for glomerular disorders.
- Open Access
- 23 June 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2519832
The exocyst in ciliogenesis
The primary cilium is an organelle found on different cell types in many organs, and is important for human health including the kidney. Diseases due to abnormal or absent cilia are termed ciliopathies and ADPKD is one of the most common ciliopathies and the fourth leading cause of ESKD. The mechanisms of how primary cilia work remain incompletely understood. One particular axis of ciliary function that is especially unclear is the role of the highly-conserved eight-subunit exocyst trafficking complex, which is critically involved in transporting proteins from the trans-Golgi network to the cilium. The goal of this review article is to cover key aspects of exocyst function, how these are known to or are predicted to impinge on ciliary function, and to point out areas that need further research. The exocyst has been shown to be regulated by many different small GTPases of the Rho, Ral, Rab, and Arf families which likely give the exocyst specificity of function. The exocyst has been implicated in several intracellular signaling pathways involving the cilium including the MAPK and phosphoinositide pathways. The exocyst and its regulators have also been found in urinary extracellular vesicles suggesting that the exocyst may be involved in 'urocrine' signaling and repair following AKI. There is an urgent need to develop new strategies to address exocyst function in the context of cilia, which will greatly benefit our understanding of cilia as well as how disrupted exocyst function in cilia leads to disease, which, in turn, should lead to novel therapeutics.
- 23 June 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2519832
Open AccessThe exocyst in ciliogenesis
The primary cilium is an organelle found on different cell types in many organs, and is important for human health including the kidney. Diseases due to abnormal or absent cilia are termed ciliopathies and ADPKD is one of the most common ciliopathies and the fourth leading cause of ESKD. The mechanisms of how primary cilia work remain incompletely understood. One particular axis of ciliary function that is especially unclear is the role of the highly-conserved eight-subunit exocyst trafficking complex, which is critically involved in transporting proteins from the trans-Golgi network to the cilium. The goal of this review article is to cover key aspects of exocyst function, how these are known to or are predicted to impinge on ciliary function, and to point out areas that need further research. The exocyst has been shown to be regulated by many different small GTPases of the Rho, Ral, Rab, and Arf families which likely give the exocyst specificity of function. The exocyst has been implicated in several intracellular signaling pathways involving the cilium including the MAPK and phosphoinositide pathways. The exocyst and its regulators have also been found in urinary extracellular vesicles suggesting that the exocyst may be involved in 'urocrine' signaling and repair following AKI. There is an urgent need to develop new strategies to address exocyst function in the context of cilia, which will greatly benefit our understanding of cilia as well as how disrupted exocyst function in cilia leads to disease, which, in turn, should lead to novel therapeutics.
- Open Access
- 2 February 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2453010
A hidden gem on the banks of the Danube River—our experience at the 28 th Budapest Nephrology School
- 2 February 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2453010
Open AccessA hidden gem on the banks of the Danube River—our experience at the 28 th Budapest Nephrology School
- 1 July 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (1) , F61-F76
Cilia-deficient renal tubule cells are primed for injury with mitochondrial defects and aberrant tryptophan metabolism
Mitochondria are centrally involved in acute kidney injury (AKI). Here, we show that cilia-deficient renal tubule cells both in vitro in cell culture and in vivo in mice are primed for injury with mitochondrial defects and aberrant tryptophan metabolism. These data suggest therapeutic strategies such as enhancing ciliogenesis or improving mitochondrial function to protect patients at risk for AKI.
- 1 July 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (1) , F61-F76
Cilia-deficient renal tubule cells are primed for injury with mitochondrial defects and aberrant tryptophan metabolism
Mitochondria are centrally involved in acute kidney injury (AKI). Here, we show that cilia-deficient renal tubule cells both in vitro in cell culture and in vivo in mice are primed for injury with mitochondrial defects and aberrant tryptophan metabolism. These data suggest therapeutic strategies such as enhancing ciliogenesis or improving mitochondrial function to protect patients at risk for AKI.
- Open Access
- 31 May 2024
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 43 (3) , 313-325
High water intake induces primary cilium elongation in renal tubular cells
Background: The primary cilium protrudes from the cell surface and functions as a mechanosensor. Recently, we found that water intake restriction shortens the primary cilia of renal tubular cells, and a blockage of the shortening disturbs the ability of the kidneys to concentrate urine. Here, we investigate whether high water intake (HWI) alters primary cilia length, and if so, what is its underlying mechanism and its role on kidney urine production. Methods: Experimental mice were given free access to normal water (normal water intake) or 3% sucrose-containing water for HWI for 2 days. Some mice were administered with U0126 (10 mg/kg body weight), an inhibitor of MEK kinase, from 2 days before HWI, daily. The primary cilium length and urine amount and osmolality were investigated. Results: HWI-induced diluted urine production and primary cilium elongation in renal tubular cells. HWI increased the expression of α-tubulin acetyltransferase 1 (αTAT1), leading to the acetylation of α-tubulins, a core protein of the primary cilia. HWI also increased phosphorylated ERK1/2 (p-ERK1/2) and exocyst complex component 5 (Exoc5) expression in the kidneys. U0126 blocked HWI-induced increases in αTAT1, p-ERK1/2, and Exoc5 expression. U0126 inhibited HWI-induced α-tubulin acetylation, primary cilium elongation, urine amount increase, and urine osmolality decrease. Conclusion: These results show that increased water intake elongates the primary cilia via ERK1/2 activation and that ERK inhibition prevents primary cilium elongation and diluted urine production. These data suggest that the elongation of primary cilium length is associated with the production of diluted urine.
- 31 May 2024
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 43 (3) , 313-325
Open AccessHigh water intake induces primary cilium elongation in renal tubular cells
Background: The primary cilium protrudes from the cell surface and functions as a mechanosensor. Recently, we found that water intake restriction shortens the primary cilia of renal tubular cells, and a blockage of the shortening disturbs the ability of the kidneys to concentrate urine. Here, we investigate whether high water intake (HWI) alters primary cilia length, and if so, what is its underlying mechanism and its role on kidney urine production. Methods: Experimental mice were given free access to normal water (normal water intake) or 3% sucrose-containing water for HWI for 2 days. Some mice were administered with U0126 (10 mg/kg body weight), an inhibitor of MEK kinase, from 2 days before HWI, daily. The primary cilium length and urine amount and osmolality were investigated. Results: HWI-induced diluted urine production and primary cilium elongation in renal tubular cells. HWI increased the expression of α-tubulin acetyltransferase 1 (αTAT1), leading to the acetylation of α-tubulins, a core protein of the primary cilia. HWI also increased phosphorylated ERK1/2 (p-ERK1/2) and exocyst complex component 5 (Exoc5) expression in the kidneys. U0126 blocked HWI-induced increases in αTAT1, p-ERK1/2, and Exoc5 expression. U0126 inhibited HWI-induced α-tubulin acetylation, primary cilium elongation, urine amount increase, and urine osmolality decrease. Conclusion: These results show that increased water intake elongates the primary cilia via ERK1/2 activation and that ERK inhibition prevents primary cilium elongation and diluted urine production. These data suggest that the elongation of primary cilium length is associated with the production of diluted urine.
- Open Access
- 26 April 2024
- Published by Springer Nature in Pharmacological Reports
- Vol. 76 (3) , 612-621
Role of the β2-adrenergic receptor in podocyte injury and recovery
Background: Podocytes have a remarkable ability to recover from injury; however, little is known about the recovery mechanisms involved in this process. We recently showed that formoterol, a long-acting β2-adrenergic receptor (β2-AR) agonist, induced mitochondrial biogenesis (MB) in podocytes and led to renoprotection in mice. However, it is not clear whether this effect was mediated by formoterol acting through the β2-AR or if it occurred through “off-target” effects. Methods: We genetically deleted the β2-AR specifically in murine podocytes and used these mice to determine whether formoterol acting through the podocyte β2-AR alone is sufficient for recovery of renal filtration function following injury. The podocyte-specific β2-AR knockout mice (β2-ARfl/fl/PodCre) were generated by crossing β2-AR floxed mice with podocin Cre (B6.Cg-Tg(NPHS2-cre)295Lbh/J) mice. These mice were then subjected to both acute and chronic glomerular injury using nephrotoxic serum (NTS) and adriamycin (ADR), respectively. The extent of injury was evaluated by measuring albuminuria and histological and immunostaining analysis of the murine kidney sections. Results: A similar level of injury was observed in β2-AR knockout and control mice; however, the β2-ARfl/fl/PodCre mice failed to recover in response to formoterol. Functional evaluation of the β2-ARfl/fl/PodCre mice following injury plus formoterol showed similar albuminuria and glomerular injury to control mice that were not treated with formoterol. Conclusions: These results indicate that the podocyte β2-AR is a critical component of the recovery mechanism and may serve as a novel therapeutic target for treating podocytopathies.
- 26 April 2024
- Published by Springer Nature in Pharmacological Reports
- Vol. 76 (3) , 612-621
Open AccessRole of the β2-adrenergic receptor in podocyte injury and recovery
Background: Podocytes have a remarkable ability to recover from injury; however, little is known about the recovery mechanisms involved in this process. We recently showed that formoterol, a long-acting β2-adrenergic receptor (β2-AR) agonist, induced mitochondrial biogenesis (MB) in podocytes and led to renoprotection in mice. However, it is not clear whether this effect was mediated by formoterol acting through the β2-AR or if it occurred through “off-target” effects. Methods: We genetically deleted the β2-AR specifically in murine podocytes and used these mice to determine whether formoterol acting through the podocyte β2-AR alone is sufficient for recovery of renal filtration function following injury. The podocyte-specific β2-AR knockout mice (β2-ARfl/fl/PodCre) were generated by crossing β2-AR floxed mice with podocin Cre (B6.Cg-Tg(NPHS2-cre)295Lbh/J) mice. These mice were then subjected to both acute and chronic glomerular injury using nephrotoxic serum (NTS) and adriamycin (ADR), respectively. The extent of injury was evaluated by measuring albuminuria and histological and immunostaining analysis of the murine kidney sections. Results: A similar level of injury was observed in β2-AR knockout and control mice; however, the β2-ARfl/fl/PodCre mice failed to recover in response to formoterol. Functional evaluation of the β2-ARfl/fl/PodCre mice following injury plus formoterol showed similar albuminuria and glomerular injury to control mice that were not treated with formoterol. Conclusions: These results indicate that the podocyte β2-AR is a critical component of the recovery mechanism and may serve as a novel therapeutic target for treating podocytopathies.
- 1 January 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (1) , F20-F29
β2-Adrenergic receptor agonists as a treatment for diabetic kidney disease
Diabetic nephropathy is the most common cause of ESKD. Formoterol, a long-acting β2-adrenergic receptor (β2-AR) agonist, reversed diabetic nephropathy in murine models of type 1 and 2 diabetes. In humans, there was an association with protection from progression of CKD in patients with COPD, by means of β2-AR agonist intake, compared with those without COPD. These data indicate that β2-AR agonists, especially formoterol, could be a new treatment for diabetic nephropathy and other forms of CKD.
- 1 January 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (1) , F20-F29
β2-Adrenergic receptor agonists as a treatment for diabetic kidney disease
Diabetic nephropathy is the most common cause of ESKD. Formoterol, a long-acting β2-adrenergic receptor (β2-AR) agonist, reversed diabetic nephropathy in murine models of type 1 and 2 diabetes. In humans, there was an association with protection from progression of CKD in patients with COPD, by means of β2-AR agonist intake, compared with those without COPD. These data indicate that β2-AR agonists, especially formoterol, could be a new treatment for diabetic nephropathy and other forms of CKD.
- Open Access
- 31 May 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 312-324
Shortening of primary cilia length is associated with urine concentration in the kidneys
Background: The primary cilium, a microtubule-based cellular organelle present in certain kidney cells, functions as a mechano-sensor to monitor fluid flow in addition to various other biological functions. In kidneys, the primary cilia protrude into the tubular lumen and are directly exposed to pro-urine flow and components. However, their effects on urine concentration remain to be defined. Here, we investigated the association between primary cilia and urine concentration. Methods: Mice either had free access to water (normal water intake, NWI) or were not allowed access to water (water deprivation, WD). Some mice received tubastatin, an inhibitor of histone deacetylase 6 (HDAC6), which regulates the acetylation of α-tubulin, a core protein of microtubules. Results: WD decreased urine output and increased urine osmolality, concomitant with apical plasma membrane localization of aquaporin 2 (AQP2) in the kidney. After WD, compared with after NWI, the lengths of primary cilia in renal tubular epithelial cells were shortened and HDAC6 activity decreased. WD induced deacetylation of α-tubulin without altering α-tubulin levels in the kidney. Tubastatin prevented the shortening of cilia through increasing HDAC6 activity and consequently increasing acetylated α-tubulin expression. Furthermore, tubastatin prevented the WD-induced reduction of urine output, urine osmolality increase, and apical plasma membrane localization of AQP2. Conclusions: WD shortens primary cilia length through HDAC6 activation and α-tubulin deacetylation, while HDAC6 inhibition blocks the WD-induced changes in cilia length and urine output. This suggests that cilia length alterations are involved, at least in part, in the regulation of body water balance and urine concentration.
- 31 May 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 312-324
Open AccessShortening of primary cilia length is associated with urine concentration in the kidneys
Background: The primary cilium, a microtubule-based cellular organelle present in certain kidney cells, functions as a mechano-sensor to monitor fluid flow in addition to various other biological functions. In kidneys, the primary cilia protrude into the tubular lumen and are directly exposed to pro-urine flow and components. However, their effects on urine concentration remain to be defined. Here, we investigated the association between primary cilia and urine concentration. Methods: Mice either had free access to water (normal water intake, NWI) or were not allowed access to water (water deprivation, WD). Some mice received tubastatin, an inhibitor of histone deacetylase 6 (HDAC6), which regulates the acetylation of α-tubulin, a core protein of microtubules. Results: WD decreased urine output and increased urine osmolality, concomitant with apical plasma membrane localization of aquaporin 2 (AQP2) in the kidney. After WD, compared with after NWI, the lengths of primary cilia in renal tubular epithelial cells were shortened and HDAC6 activity decreased. WD induced deacetylation of α-tubulin without altering α-tubulin levels in the kidney. Tubastatin prevented the shortening of cilia through increasing HDAC6 activity and consequently increasing acetylated α-tubulin expression. Furthermore, tubastatin prevented the WD-induced reduction of urine output, urine osmolality increase, and apical plasma membrane localization of AQP2. Conclusions: WD shortens primary cilia length through HDAC6 activation and α-tubulin deacetylation, while HDAC6 inhibition blocks the WD-induced changes in cilia length and urine output. This suggests that cilia length alterations are involved, at least in part, in the regulation of body water balance and urine concentration.